Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Eli Lilly And Co (LLY) Price & Performance

Acadia Healthcare Company Inc
Eli Lilly And Co

Price performance

Price movement over the last 24 hours

Key statistics

Acadia Healthcare Company Inc vs Eli Lilly And Co — how do they compare? Acadia Healthcare Company Inc trades at $30.71 (market cap $2.94B), while Eli Lilly And Co trades at $1,221.08 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 374.1× Acadia Healthcare Company Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.

ACHCLLY
Market Cap
$2.94B$1.10T
Sector
HealthHealth
52-Week High
$31.92$1.24K
52-Week Low
$11.68$625.65
Enterprise Value
$5.45B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.

The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.

The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY